QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=3F5DFB266FBDD5A19ACBEA654DC8EC54;jsessionid=CF323899DE1C3F386C07DC837372A6D7;jsessionid=540AEBB216705AFA3979ACDD2A167D4E;jsessionid=8CE6000CDDECF37CE8063E266F0C4F74;jsessionid=C548E35437916D42DAAFF198433AEE4E;jsessionid=42CE59F47596AD57693B93C21E6580ED;jsessionid=457F43455CF4C1600DBD0EEE5F89318D (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=3F5DFB266FBDD5A19ACBEA654DC8EC54;jsessionid=CF323899DE1C3F386C07DC837372A6D7;jsessionid=540AEBB216705AFA3979ACDD2A167D4E;jsessionid=8CE6000CDDECF37CE8063E266F0C4F74;jsessionid=C548E35437916D42DAAFF198433AEE4E;jsessionid=42CE59F47596AD57693B93C21E6580ED;jsessionid=457F43455CF4C1600DBD0EEE5F89318D